World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer
(Thomson Reuters ONE) -
YOKOHAMA, Japan, Oct. 18, 2017 (GLOBE NEWSWIRE) -- The final press conference
from the International Association for the Study of Lung Cancer (IASLC)
18th World Conference on Lung Cancer (WCLC) highlighted new advancements
surrounding the discovery of PD-1 and PD-L1, including a discussion from the
researcher credited with discovering PD-1, as well as interventions to prevent
lung cancer and improve quality of life for lung cancer patients.
Innovations in lung cancer treatment linked to the discovery of PD-1
Prof. Tasuku Honjo of Japan, who was the first to identify PD-1 in 1992, shared
an update on how PD-1 blockers have been widely used to treat many types of
cancers. After decades of study, research into PD-1 has led to breakthrough
immunotherapy treatments that are being hailed as a "penicillin moment" in
cancer treatment.
"I believe that, just as a number of antibiotics developed in the wake of the
discovery of penicillin now protect humans against threats of infectious
diseases, this discovery will play a leading role in advancement of cancer
immunotherapy," said Prof. Honjo. "In the future, the fear of dying from cancer
will cease to exist."
Extensive research into combination therapy has been undertaken by a number of
institutions. Specifically, Prof. Honjo felt that PD-1 blockade combinatorial
therapy using mitochondrial activators, especially PGC-1(alpha) activators, may
be promising.
International Association for the Study of Lung Cancer Blueprint II
Dr. Fred Hirsch of the United States and Dr. Ming Tsao of Canada shared an
exciting update on Phase 2 of the PD-L1 Blueprint Project.
The project began in 2014 during a workshop led by the U.S. Food and Drug
Administration (FDA), the American Association for Cancer Research (AACR) and
the American Society of Clinical Oncology (ASCO). As a result of the workshop,
the PD-L1 Blueprint Project was established, with the primary goal of comparing
the PD-L1 assays used in clinical trials in terms of analytical and diagnostic
performance. The consortium behind the Blueprint Project included
representatives from Bristol-Myers Squibb (BMS), Merck, Genentech/Roche,
AstraZeneca, Dako, Ventana and AACR, as well as the IASLC, which is coordinating
the project.
"In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status
remains a clinical challenge," said Dr. Hirsch. "The major strength of the PD-L1
Blueprint Project is the unique partnership among the different pharmaceutical
companies and diagnostic companies, with the IASLC as the coordinating
organization."
The Blueprint phase 1 comparability study demonstrated that three PD-L1 assays
(28-8, 22C3, SP263) showed comparable analytical performance for assessment of
PD-L1 expression on tumor cells, while the SP-142 PD-L1 assay appeared to stain
a lower percentage of tumor cells compared to the other assays. In contrast, all
assays stained tumor infiltrating immune cells, but with poor concordance
between assays. The Blueprint phase 2 study involving routine clinical lung
cancer samples and 25 pathologists largely affirms the blueprint 1 results, thus
three of the PD-L1 assays, 22C3, 28-8 and SP263 are comparable for tumor cell
staining. The results also showed that pathologists are strongly reliable in
scoring the PD-L1 expression on tumor cells, and scoring by glass slides and
digital images are comparable.
Community engagement interventions may reduce disparities in lung cancer
outcomes among minorities
Community-based interventions implemented in minority community sites resulted
in changes in participants' knowledge, attitudes and beliefs about cancer, as
well as perceived benefits and self-efficacy measures regarding lung cancer
screening, as uncovered in research presented by Dr. Lovoria Williams of August
University in the United States. These findings are critical to addressing the
significant lung cancer survival rate disparities in racial and ethnic
minorities and the medically underserved. Read the full press release here.
Exercise interventions in advanced lung cancer patients led to increased
functionality, which may be linked to quality of life benefits
Physical exercise and psycho-social interventions in patients with advanced
stage lung cancer improved functional capacity, which may be linked to quality
of life benefits. The exercise group was found to have improved functional
capacity at the conclusion of the intervention and reported a significant
improvement in quality of life, which may be linked to the improved
functionality, according to Dr. Morten Quist of the University of Copenhagen in
Denmark. To read the full press release, click here.
Livestreams of the daily press conferences are available here.
About the WCLC
The World Conference on Lung Cancer (WCLC) is the world's largest meeting
dedicated to lung cancer and other thoracic malignancies, attracting over 6,000
researchers, physicians and specialists from more than 100 countries. The goal
is to disseminate the latest scientific achievements; increase awareness,
collaboration and understanding of lung cancer; and to help participants
implement the latest developments across the globe. Organized under the theme of
"Synergy to Conquer Lung Cancer," the conference will cover a wide range of
disciplines and unveil several research studies and clinical trial results. For
more information, visit wclc2017.iaslc.org.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only
global organization dedicated to the study of lung cancer and other thoracic
malignancies. Founded in 1974, the association's membership includes more than
6,500 lung cancer specialists across all disciplines in over 100 countries,
forming a global network working together to conquer lung and thoracic cancers
worldwide. The association also publishes the Journal of Thoracic Oncology, the
primary educational and informational publication for topics relevant to the
prevention, detection, diagnosis and treatment of all thoracic malignancies.
Visit www.iaslc.org for more information.
Contacts:
Hillary Wasserman
Senior Associate
HWasserman(at)GroupGordon.com
+1 732-778-1896
Becky Bunn, MSc
Public Relations Manager
Becky.Bunn(at)IASLC.org
+1 720-254-9509
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IASLC via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="European Lithium to Fast-Track Completion of PFS at Wolfsberg Lithium ProjectDatum: 18.10.2017 - 06:25 Uhr
Sprache: Deutsch
News-ID 564070
Anzahl Zeichen: 7346
contact information:
Town:
Aurora, Colorado
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"World Conference on Lung Cancer Wednesday Press Conference: PD-1/PD-L1 Advancements and Interventions to Prevent and Treat Lung Cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
IASLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
